Eli Lilly Résultats passés
Passé contrôle des critères 4/6
Eli Lilly a connu une croissance annuelle moyenne de ses bénéfices de 31.1%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en hausse à 9.7% par an. Les revenus ont augmenté de en hausse à un taux moyen de 20.8% par an. Le rendement des capitaux propres de Eli Lilly est 81% et ses marges nettes sont de 35%.
Informations clés
31.07%
Taux de croissance des bénéfices
31.32%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 5.95% |
| Taux de croissance des recettes | 20.77% |
| Rendement des fonds propres | 81.02% |
| Marge nette | 34.99% |
| Prochaine mise à jour des résultats | 05 Aug 2026 |
Mises à jour récentes des performances passées
Recent updates
Seeking Alpha • May 19
Eli Lilly Is A Buy (Technical Analysis)
Summary Eli Lilly exhibits strong bullish technicals, with price action, momentum, and relative strength all supporting a continued uptrend. Despite an 'F' valuation grade, LLY's growth, profitability, and upward earnings revisions reinforce its investment appeal. Recent earnings beat expectations, with Q1 EPS of $8.55 and revenue of $19.8B; 2026 guidance was raised. Institutional accumulation is evident, and I would reconsider my position only if LLY closes below its 30-week EMA. Read the full article on Seeking Alpha
Mise à jour du récit • May 07
LLY: Obesity Pricing Pressure And Safety Headlines Will Shape Future Franchise Economics
Analysts have raised Eli Lilly's implied fair value from $883.99 to $899.73 after several firms increased their price targets by $1 to $50, citing confidence in the obesity and diabetes pipeline, Foundayo's regulatory progress, and clarifications around recent safety concerns. Analyst Commentary Recent research on Eli Lilly reflects a mix of enthusiasm around obesity and diabetes assets and a clearer, more cautious minority that is focused on how much optimism is already reflected in the stock.
Mise à jour du récit • Apr 20
LLY: Obesity And Diabetes Platform Will Support Premium Positioning Beyond 2030
Analysts have slightly raised their average price targets on Eli Lilly in recent weeks, citing supportive trial updates in obesity and diabetes, favorable comparisons to competing GLP-1 therapies, and regulatory progress that they say supports high but unchanged fair value estimates of around $1,500. Analyst Commentary Recent Street research around Eli Lilly has been active, with a cluster of price target moves, rating changes, and product specific notes that give you a clearer sense of how professionals are framing the risk and reward.
Mise à jour du récit • Apr 06
LLY: Oral GLP-1 Launch And Capacity Expansion Will Drive Future Obesity Upside
Analysts have nudged Eli Lilly's price target slightly higher by $1, reflecting updated views on obesity and diabetes franchises following recent Foundayo approval commentary and comparative GLP-1 data. Analyst Commentary Recent research on Eli Lilly clusters around obesity and diabetes, pricing dynamics in GLP-1 therapies, and the implications of new product approvals and trial readouts for long term growth and valuation.
Nouveau récit • Mar 25
Eli Lilly: A Pipeline-Driven Growth Story Trading 30% Below What the Business Is Actually Worth
Eli Lilly already runs one of the fastest-growing drug businesses on earth, and its most powerful drug is not even approved yet. WHERE THE STOCK SITS TODAY The current price is around $907 (25/03/2026).Mise à jour du récit • Mar 23
LLY: Obesity And Diabetes Franchise Strength Will Support Premium Positioning
Analysts have raised their price target for Eli Lilly to $1,500, citing updated models that reflect slightly stronger assumed revenue growth, a marginally higher profit margin profile, and continued confidence in the obesity and diabetes franchises following recent trial data and supportive sell side research. Analyst Commentary Recent research highlights a split view on Eli Lilly, with some bullish analysts leaning into the obesity and diabetes opportunity set, while at least one more cautious voice questions how much growth is already reflected in the share price.Mise à jour du récit • Mar 09
LLY: Obesity Drug Leadership And Pipeline Catalysts Will Sustain Premium Positioning
The updated analyst price target for Eli Lilly has increased to $1,490.52 from $1,429.89. Analysts highlight the obesity and GLP-1 franchise, premium valuations tied to weight loss leadership, and potential upside from pipeline and acquisition catalysts as key factors supporting this change.Mise à jour du récit • Feb 23
LLY: GLP-1 Obesity Leadership Will Drive Future Cardiometabolic And M&A Upside
Eli Lilly's analyst price targets have shifted higher, with our fair value estimate moving from $1,093.22 to $1,211.21, as analysts point to sustained GLP-1 obesity leadership, premium valuation support, and an expanding cardiometabolic pipeline as key drivers of their updated views. Analyst Commentary Recent Street research on Eli Lilly clusters around a few clear themes, with bullish analysts focusing on obesity leadership, cardiometabolic breadth, and M&A, while more cautious voices watch valuation and execution risk around the pipeline.Mise à jour du récit • Feb 08
LLY: Government Pricing Deals Will Compress Obesity Franchise Economics Going Forward
Analysts have raised their fair value estimate for Eli Lilly from US$770 to about US$884 per share, reflecting updated assumptions on long term obesity opportunities, recent price target increases across several firms, and steady expectations around margins and future P/E multiples. Analyst Commentary The latest batch of research on Eli Lilly revolves around its weight loss and cardiometabolic franchises, expectations for new product launches, and the implications of recent policy developments on pricing and access.Article d’analyse • Feb 07
Eli Lilly and Company (NYSE:LLY) Just Released Its Yearly Earnings: Here's What Analysts Think
Investors in Eli Lilly and Company ( NYSE:LLY ) had a good week, as its shares rose 2.0% to close at US$1,058 following...Mise à jour du récit • Jan 25
LLY: Government GLP 1 Pricing Deals Will Pressure Obesity Margins
Analysts have nudged their price targets on Eli Lilly slightly higher, citing continued confidence in the obesity and GLP 1 franchise, supportive government pricing agreements, and potential upside from acquisitions and pipeline catalysts, even as some firms fine tune their models and individual targets by low single digit amounts such as Guggenheim's recent US$2 trim. Analyst Commentary Recent research on Eli Lilly has been dominated by optimism around obesity treatments and government pricing agreements, but there is also a pocket of caution that is worth paying attention to if you are thinking about valuation, execution and long term growth risk.Mise à jour du récit • Jan 11
LLY: GLP-1 Pricing Deals Will Pressure Obesity Margins Going Forward
Analysts lifted their fair value estimate for Eli Lilly from US$650 to US$770, citing higher assumed profit margins, a slightly higher discount rate, updated expectations for revenue growth and future P/E, and continued Street support related to the obesity franchise, GLP-1 pricing agreements, and pipeline catalysts. Analyst Commentary Recent Street research around Eli Lilly has been dominated by views on obesity drugs, pricing agreements with the U.S. government, and the company’s expanding pipeline.Mise à jour du récit • Dec 27
LLY: GLP-1 Pricing Deals And Policy Will Shape Future Obesity Leadership And Risks
Analysts have lifted their fair value estimate for Eli Lilly to approximately $1,093 from about $1,024, reflecting expectations for stronger long term GLP 1 driven revenue growth, expanding profit margins and sustained leadership in the obesity market, supported by recent U.S. reimbursement and pricing deals. Analyst Commentary Street research remains broadly constructive on Eli Lilly, with a series of upward price target revisions and fresh coverage initiations underscoring confidence in the durability of its GLP 1 franchise and broader innovation pipeline.Mise à jour du récit • Dec 13
LLY: Government Access Deals Will Drive Durable Obesity And Diabetes Leadership
Analysts have raised their fair value estimate for Eli Lilly shares from approximately $1,170 to about $1,430 per share, reflecting higher expected profitability and sustained leadership in the GLP 1 obesity and diabetes market, supported by recent U.S. government access deals and upcoming launches such as orforglipron. Analyst Commentary Bullish analysts continue to frame Eli Lilly as a core beneficiary of the expanding obesity and diabetes treatment market, with valuation upside tied to both higher GLP 1 penetration and a broadening metabolic pipeline.Mise à jour du récit • Nov 29
LLY: Upcoming Price Discounts And Policy Decisions Will Influence Drug Market Leadership And Risks
Eli Lilly's analyst price target has increased by approximately $21 to $1,024. Analysts cite earnings upside, expanding obesity drug opportunities, and recently announced government reimbursement agreements as key drivers of improved growth and profitability expectations.Article d’analyse • Nov 25
Investors Appear Satisfied With Eli Lilly and Company's (NYSE:LLY) Prospects As Shares Rocket 30%
Despite an already strong run, Eli Lilly and Company ( NYSE:LLY ) shares have been powering on, with a gain of 30% in...
Mise à jour du récit • Nov 21
GLP-1 drugs part of medicare
Short update, this is more bullish news about the demand for GLP-1 drugs in general spurring growth in this type of weight loss drug. Also, earnings report have showed that increase in earnings have been driven by increase in volume of GLP-1 drugs.Mise à jour du récit • Nov 15
LLY: Upcoming Drug Price Reductions and Policy Debates Will Shape Future Opportunities and Risks
The analyst price target for Eli Lilly has increased by over $80 to approximately $1,003 per share. Analysts point to accelerating revenue growth, higher profit margins, and ongoing strength in the company's obesity drug franchise as drivers of greater long-term value.Article d’analyse • Nov 07
Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Eli Lilly and Company's ( NYSE:LLY ) stock was strong after they recently reported robust earnings. However, we think...Mise à jour du récit • Nov 01
LLY: Upcoming Drug Launches And Global Expansion Will Shape Future Outlook
Eli Lilly’s fair value estimate has increased from $891.62 to $919.33. This reflects analysts' upward price target revisions following stronger than expected quarterly results and an improved earnings outlook.Nouveau récit • Sep 19
Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions
Catalysts Mounjaro/Zepbound: Lilly’s tirzepatide franchise is the engine of growth. Mounjaro (for type 2 diabetes) and Zepbound (obesity) each grew rapidly in 2024.Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Eli Lilly gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 72,249 | 25,277 | 11,560 | 14,113 |
| 31 Dec 25 | 65,179 | 20,640 | 11,094 | 13,337 |
| 30 Sep 25 | 59,421 | 18,412 | 10,513 | 12,559 |
| 30 Jun 25 | 53,259 | 13,800 | 9,871 | 11,827 |
| 31 Mar 25 | 49,004 | 11,106 | 9,226 | 11,202 |
| 31 Dec 24 | 45,043 | 10,590 | 8,594 | 10,991 |
| 30 Sep 24 | 40,863 | 8,370 | 7,633 | 10,531 |
| 30 Jun 24 | 38,923 | 7,342 | 7,337 | 10,206 |
| 31 Mar 24 | 35,932 | 6,138 | 7,144 | 9,851 |
| 31 Dec 23 | 34,124 | 5,240 | 7,404 | 9,313 |
| 30 Sep 23 | 32,073 | 4,988 | 6,682 | 8,747 |
| 30 Jun 23 | 29,516 | 6,498 | 6,515 | 8,140 |
| 31 Mar 23 | 27,691 | 5,687 | 6,236 | 7,566 |
| 31 Dec 22 | 28,541 | 6,245 | 6,068 | 7,191 |
| 30 Sep 22 | 29,240 | 6,033 | 6,037 | 7,093 |
| 30 Jun 22 | 29,071 | 5,692 | 6,020 | 6,996 |
| 31 Mar 22 | 29,323 | 6,129 | 6,104 | 6,869 |
| 31 Dec 21 | 28,318 | 5,582 | 6,142 | 6,931 |
| 30 Sep 21 | 27,759 | 5,972 | 6,119 | 6,870 |
| 30 Jun 21 | 26,726 | 6,071 | 6,069 | 6,631 |
| 31 Mar 21 | 25,486 | 6,093 | 5,867 | 6,366 |
| 31 Dec 20 | 24,540 | 6,194 | 5,869 | 5,976 |
| 30 Sep 20 | 23,214 | 5,573 | 6,019 | 5,829 |
| 30 Jun 20 | 22,950 | 5,618 | 5,924 | 5,745 |
| 31 Mar 20 | 23,087 | 5,533 | 6,048 | 5,757 |
| 31 Dec 19 | 22,320 | 4,638 | 6,004 | 5,595 |
| 30 Sep 19 | 21,843 | 4,264 | 5,984 | 5,405 |
| 30 Jun 19 | 21,673 | 4,103 | 6,019 | 5,305 |
| 31 Mar 19 | 21,622 | 2,545 | 5,913 | 5,174 |
| 31 Dec 18 | 21,493 | 3,151 | 5,735 | 5,051 |
| 30 Sep 18 | 22,016 | 372 | 5,855 | 5,146 |
| 30 Jun 18 | 22,368 | -166 | 5,975 | 5,205 |
| 31 Mar 18 | 22,607 | 1,074 | 6,210 | 5,207 |
| 31 Dec 17 | 19,974 | -86 | 5,733 | 5,096 |
| 30 Sep 17 | 22,471 | 2,225 | 6,475 | 5,321 |
| 30 Jun 17 | 22,005 | 2,447 | 6,526 | 5,217 |
| 31 Mar 17 | 21,585 | 2,187 | 6,483 | 5,281 |
| 31 Dec 16 | 21,222 | 2,738 | 6,330 | 5,310 |
| 30 Sep 16 | 20,837 | 2,444 | 6,460 | 5,238 |
| 30 Jun 16 | 20,605 | 2,466 | 6,471 | 5,145 |
| 31 Mar 16 | 20,179 | 2,319 | 6,483 | 4,978 |
| 31 Dec 15 | 19,959 | 2,408 | 6,533 | 4,796 |
| 30 Sep 15 | 19,704 | 2,359 | 6,535 | 4,538 |
| 30 Jun 15 | 19,620 | 2,059 | 6,631 | 4,638 |
Des revenus de qualité: LLY a un niveau élevé de bénéfices non monétaires.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de LLY sont plus élevées que l'année dernière LLY. (35%) sont plus élevées que l'année dernière (22.7%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de LLY ont augmenté de manière significative de 31.1% par an au cours des 5 dernières années.
Accélération de la croissance: La croissance des bénéfices de LLY au cours de l'année écoulée ( 127.6% ) dépasse sa moyenne sur 5 ans ( 31.1% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices LLY au cours de l'année écoulée ( 127.6% ) a dépassé celle du secteur Pharmaceuticals -5%.
Rendement des fonds propres
ROE élevé: Bien que le retour sur capitaux propres ( 81.02% ) de LLY soit exceptionnel, cette mesure est faussée en raison de son niveau d'endettement élevé.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/20 09:50 |
| Cours de l'action en fin de journée | 2026/05/20 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Eli Lilly and Company est couverte par 53 analystes. 28 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |